ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1421

Preclinical Interstitial Lung Disease in Early Rheumatoid Arthritis

Javier Narváez1, Alejandro Robles Perez2, Maria Molina Molina3 and Joan Miquel Nolla4, 1Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 2Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitario de Bellvitge, Barcelona, Spain, 4Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Diagnostic Tests, Lung Disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose: Early detection and treatment of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) may ameliorate disease progression. The objective of the present study was to: 1) study the frequency of asymptomatic preclinical ILD in early RA patients, in order to determine how early the lungs are affected in the disease and establish whether it is clinically advantageous to systematically screen asymptomatic patients for this complication; and 2) study the potential association of anti-citrullinated peptide antibody (ACPA) positivity with RA-ILD

Methods: Observational prospective study of a cohort of early RA patients (joint symptoms < 2 years) who did not present respiratory symptoms and were included in an ILD screening program via baseline chest radiograph and complete pulmonary function tests (PFT). In patients with lung abnormalities in the chest radiograph or any restriction or impaired diffusion, defined as < 80% of predicted forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO) respectively, the study was completed with a high-resolution computerized tomography scan (HRCT) of the chest.

Results: Forty patients (30 women) were included in the study, with PFR alterations detected in 18 (45%). All cases had a DLCO < 80% of predicted (mean 68%; range 43% to 78%), without significant reduction in the FVC values. The HRCT detected abnormalities in only 7 of these 18 patients: 1 radiographic pattern suggestive of non-specific interstitial pneumonia (NSIP); 1 radiographic pattern of respiratory bronchiolitis-associated interstitial lung disease (RB-ILD); the other 5 had bronchiectasis in the absence of fibrosis, emphysema or pulmonary nodules. In 11 patients with DLCO alterations, the HRCT was normal, and in none of these cases could the alteration be attributed to the presence of anemia.

A significant inverse correlation between ACPA levels and baseline DLCO was found. We also observed, a significant association between the severity of disease activity as measured by DAS28-CRP and baseline DLCO values.

Conclusion:   Asymptomatic preclinical ILD, which is detectable by restrictive abnormalities in PFT (mainly, DLCO < 80% of predicted), is common (45%) among patients with early RA. PFT screening may be indicated for such patients since early detection of these alterations could change the course of the lung disease if risk factors (such as smoking or environmental exposures) are avoided, infections are prevented and drugs for RA treatment are selected that are less harmful to the lung. Our data also support a relationship between high ACPA levels and the occurrence of RA-ILD.


Disclosure:

J. Narváez,
None;

A. Robles Perez,
None;

M. Molina Molina,
None;

J. M. Nolla,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preclinical-interstitial-lung-disease-in-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology